XIV Eurasian Hematology-Oncology Congress - EHOC 2023

 

XIV Eurasian Hematology-Oncology Congress - EHOC 2023
R

Debates in MPNs: IFN-α is the Optimal 1L Treatment for Young PV Patients

By XIV Eurasian Hematology-Oncology Congress - EHOC 2023 FEATURING Rajko Kusec
By XIV Eurasian Hematology-Oncology Congress - EHOC 2023 FEATURING Rajko Kusec
0 views
February 21, 2024
0 Comments
Login to view comments. Click here to Login
MDS and MPN
12:28
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Next Questions in MDS

Feat. G. Garcia-Manero
10:11
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Case Presentation: A Patient With Polycythemia, Thrombocytopenia, &a…

Feat. M. Mittelman
20:35
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Treatment Options for MDS With Ring Sideroblasts: A Case-Based Discu…

Feat. M. Çetiner
14:36
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Optimizing the Management of Low-Risk MDS

Feat. U. Platzbecker
19:32
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Current State-of-the-Art in MDS

Feat. M. Mittelman
10:08
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Advances and Unmet Needs in MPN Treatment

Feat. D. Cilloni
06:58
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Debates in MPNs: IFN-α is the Optimal 1L Treatment for Young PV Pati…

Feat. R. Kusec
08:47
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Debates in MPNs: Hydroxyurea is the Optimal 1L Treatment for Young P…

Feat. E. Eşkazan
07:58
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Updates in the Prognosis and Treatment of Myelofibrosis

Feat. S. Koçak Toprak
10:50
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

CBL Mutated MPNs: Overview and Case Discussion

Feat. A. Lucchesi
19:05
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Key Biological and Clinical Developments in MPNs

Feat. T. Mughal